Evidence map›Paper›PMID 41801508›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Racial/ethnic and geographic differences in second primary cancers in stomach cancer survivors: a comparative study of U.S. and South Korea.

Yuntong Wang, Dong-Woo Choi, Sangwon Lee, Jialin Mao, Art Sedrakyan, Xiang Shu, Kui Son Choi, Heejung Chae, Eunji Choi

Abstract readComparative Study
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuntong Wang *Department of Population Health Sciences, Weill Cornell Medicine, 425 E 61st Street, New York, NY, 10065, USA.
Dong-Woo Choi *National Cancer Control Institute, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea.
Sangwon LeeNational Cancer Control Institute, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea.
Jialin MaoDepartment of Population Health Sciences, Weill Cornell Medicine, 425 E 61st Street, New York, NY, 10065, USA.
Art SedrakyanDepartment of Population Health Sciences, Weill Cornell Medicine, 425 E 61st Street, New York, NY, 10065, USA.
Xiang ShuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kui Son ChoiNational Cancer Control Institute, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea.
Heejung Chae *National Cancer Control Institute, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea.
Eunji Choi *Department of Population Health Sciences, Weill Cornell Medicine, 425 E 61st Street, New York, NY, 10065, USA. euc4006@med.cornell.edu.ORCID 0000-0003-1315-1433

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigationR37CA283041 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Xiang Shu · 2024 to 2026
$2.2M
Prospective metabolomics investigation of gastric cancer risk in African Americans and European Whites with a low socioeconomic statusR56CA283041 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHU, XIANG · 2023 to 2023
$300k
National Cancer Center NCC- 24H1062NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA283041NCI NIH HHS R56 CA283041
6 · The paper itself

Abstract

backgroundStomach cancer remains the fifth leading cause of cancer death, with racial/ethnic and geographic differences. As survival improves, these survivors face elevated risks of second primary cancers (SPCs). We evaluated SPC risk and post-SPC survival by race/ethnicity and between the U.S. and South Korea.

methodsWe analyzed patients with stage I-III stomach cancer (2012-2020) from the U.S. SEER-17 and Korea Cancer Public-Library Database. SPCs were defined as non-gastric cancers diagnosed > 1 year post initial diagnosis. Cumulative SPC incidence was estimated using Aalen-Johansen method to account for competing death. Cox regression assessed survival impact of SPC development.

resultsAmong 19,595 U.S. and 204,240 Korean patients, 1,050 and 6,908 developed SPCs, respectively. In the U.S., 5-year SPC incidence was highest in Black (7.4% [6.1-8.6]) and lowest in Pacific Islanders (4.5% [2.3-6.7]). Notable heterogeneity in SPC incidence was observed across Asian subgroups, with Korean Americans showing the highest (6.9% [4.7-9.1]) and Filipinos the lowest (4.4% [1.9-7.2]). In contrast, Korean survivors in South Korea had the lowest SPC incidence (3.8% [3.7-3.9]). SPC development was associated with higher mortality (HR = 2.22 [1.96-2.52]), with a stronger effect in Asians (HR = 3.12) than Whites (HR = 1.96; interaction P < 0.1). Among Asian subgroups, SPC development was associated with the highest mortality in Vietnamese (HR = 13.6) and the lowest in Filipino survivors (HR = 1.54; interaction P < 0.01). Among Korean survivors in South Korea, SPC development conferred a modest increase in mortality risk (HR = 1.68 [1.61-1.75]).

conclusionsSPC risk and outcomes in stomach cancer survivors vary by race/ethnicity and country, particularly within Asian subgroups.

Indexed as

Cancer SurvivorsEthnicityNeoplasms, Second PrimaryStomach NeoplasmsAgedEast Asian PeopleFemaleHumansIncidenceMaleMiddle AgedRepublic of KoreaSEER ProgramSurvival RateUnited StatesWhiteEpidemiologyIncidenceMortalityMultiple primary cancerRacial/ethnic disapritySecond primary cancer

Identifiers

PMID41801508
PMCPMC13124850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.